Model I predicts the observed pre-dose means adequately, but tends to overpredict the
peak. Model II tends to underpredict the pre-dose means, but adequately describes the …

Background—Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke
prevention in atrial fibrillation. The purpose of this study was to compare their risks of …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Background This register-based observational study compares dabigatran to warfarin for
secondary stroke prevention in atrial fibrillation patients among both “new starters” on …

Background—Recent studies have investigated alternatives to warfarin for stroke
prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost …

Objectives: The goal of this study was to analyze the impact of dabigatran plasma
concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic …

For years, warfarin and aspirin have been standard therapies for prophylaxis of stroke in
atrial fibrillation. In late 2010, dabigatran, an oral direct thrombin inhibitor, became available …

Objectives: This study sought to compare the net clinical benefit of dabigatran 110 mg bid
and 150 mg bid with that of warfarin in patients with atrial fibrillation (AF). Background: In …

Background—The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY)
trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 …

Background: Patients with atrial fibrillation should be stratified for stroke risk and the
CHADS2 is a widely accepted risk score. Warfarin reduces the risk of stroke in atrial …